Sihuan Pharmaceutical Invests in Suisselle SA

Sihuan Pharmaceutical Holdings Group (HKG:0460) announced that it has made a capital investment in Swiss medical aesthetics company Suisselle, according to a statement released on Monday to the Hong Kong Stock Exchange. The pharmaceutical group did not disclose the financial terms of the transaction.

Sihuan Pharmaceutical previously obtained the exclusive distribution rights for Suisselle’s CELLBOOSTER® skin booster in China in 2022. This new investment further reinforces their long-term collaboration. Following the investment, the Group will hold permanent exclusive distribution rights for CELLBOOSTER® products in China and will play an active role in their operation and development.

In addition, this partnership will enable both companies to use Suisselle’s European platform to promote and sell medical aesthetic products developed by “Meiyan Space”, a subsidiary of Sihuan Pharmaceutical, across Europe and other international markets. At the same time, the Group will continue to bring innovative products from Suisselle and other European companies to the Chinese market, further expanding its product portfolio.

About Suisselle SA

Founded in 2010, Suisselle is a science-driven company based in Yverdon-les-Bains in Canton of Vaud, Switzerland, specializing in the development of treatments in the field of hyaluronic acid and innovative cells area. Based on its cutting-edge innovative CHAC patented technology, it design, develop and produce the safest and the most effective professional medical aesthetic products while adhering to the highest quality standards, it has expanded its business to over 43 countries. The company is dedicating to create unique and innovative technologies for cell repair and skin rejuvenation, to offer maximum rejuvenation effect with minimal invasivity

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited
in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical focusing on medical aesthetic business. It has created a complete business
chain of “raw materials, products, and commercialization” through Meiyan Space in the
medical aesthetic field. Its products cover all basic categories of light medical aesthetic,
including filling, shaping, support, optoelectronic equipment, and skin management. Its
core product sales have occupied an important market share in China. Relying on resource
integration and commercialization capabilities, the Group is committed to becoming a leading
global provider of medical aesthetic solutions

➡️ Source: Press Release | 📸 ©Suisselle